X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TORRENT PHARMA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA TORRENT PHARMA FULFORD INDIA/
TORRENT PHARMA
 
P/E (TTM) x 398.8 44.4 898.0% View Chart
P/BV x 6.2 6.0 103.0% View Chart
Dividend Yield % 0.1 0.8 10.0%  

Financials

 FULFORD INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TORRENT PHARMA
Mar-18
FULFORD INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9421,550 60.8%   
Low Rs4501,144 39.4%   
Sales per share (Unadj.) Rs691.4354.7 194.9%  
Earnings per share (Unadj.) Rs11.540.1 28.6%  
Cash flow per share (Unadj.) Rs15.464.2 23.9%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.31.0 27.6%  
Book value per share (Unadj.) Rs380.0273.1 139.1%  
Shares outstanding (eoy) m3.90169.22 2.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.03.8 26.5%   
Avg P/E ratio x60.733.6 180.7%  
P/CF ratio (eoy) x45.321.0 216.1%  
Price / Book Value ratio x1.84.9 37.1%  
Dividend payout %17.434.9 49.9%   
Avg Mkt Cap Rs m2,714227,897 1.2%   
No. of employees `0000.414.7 3.0%   
Total wages/salary Rs m50511,353 4.4%   
Avg. sales/employee Rs Th6,073.04,083.0 148.7%   
Avg. wages/employee Rs Th1,137.4772.3 147.3%   
Avg. net profit/employee Rs Th100.7461.3 21.8%   
INCOME DATA
Net Sales Rs m2,69660,021 4.5%  
Other income Rs m1252,988 4.2%   
Total revenues Rs m2,82263,009 4.5%   
Gross profit Rs m-4613,493 -0.3%  
Depreciation Rs m154,086 0.4%   
Interest Rs m103,085 0.3%   
Profit before tax Rs m549,310 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m102,529 0.4%   
Profit after tax Rs m456,781 0.7%  
Gross profit margin %-1.722.5 -7.7%  
Effective tax rate %17.727.2 65.1%   
Net profit margin %1.711.3 14.7%  
BALANCE SHEET DATA
Current assets Rs m1,73852,623 3.3%   
Current liabilities Rs m54552,022 1.0%   
Net working cap to sales %44.31.0 4,417.1%  
Current ratio x3.21.0 315.5%  
Inventory Days Days48120 40.5%  
Debtors Days Days476 5.6%  
Net fixed assets Rs m1285,016 0.0%   
Share capital Rs m39846 4.6%   
"Free" reserves Rs m1,44345,376 3.2%   
Net worth Rs m1,48246,222 3.2%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m2,077142,432 1.5%  
Interest coverage x6.74.0 167.1%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.30.4 308.1%   
Return on assets %2.66.9 37.7%  
Return on equity %3.014.7 20.6%  
Return on capital %4.314.2 30.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1714,580 0.1%   
Fx outflow Rs m6733,600 18.7%   
Net fx Rs m-65610,980 -6.0%   
CASH FLOW
From Operations Rs m908,942 1.0%  
From Investments Rs m105-47,070 -0.2%  
From Financial Activity Rs m-1434,174 -0.0%  
Net Cashflow Rs m181-3,655 -4.9%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 7.0 54.1%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 8.8 240.9%  
Shareholders   4,783 26,511 18.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ABBOTT INDIA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red, Global Markets Cautious, and Top Stocks in Action(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in red after a volatile day of trading.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS